Medium-and-long-chain fatty acid grease-probiotic composition and application thereof in regulating blood sugar and blood fat

Abstract

The invention discloses a medium-chain and long-chain fatty acid grease-probiotic composition and application thereof in regulating blood sugar and blood lipid, the composition comprises a grease component and a probiotic component, the grease component takes myristic acid as main fatty acid, MA accounts for 50-70% of the total amount of fatty acid in grease, and the grease component is compounded with medium-chain triglyceride and high-oleic-acid sunflower seed oil. And the probiotic component is bifidobacterium pseudocatenum, and the viable count of the bifidobacterium pseudocatenum is preferably 1 * 10 < 9 >-1 * 10 < 11 > CFU / g. Animal experiments verify that the composition can significantly reduce fasting blood-glucose, improve oral glucose tolerance damage and significantly reduce serum total cholesterol and triglyceride levels. Compared with single use of MA grease or single use of Bifidobacterium pseudocatenuicola, the composition provided by the invention shows a better comprehensive effect in the aspects of regulating blood sugar and blood fat, can be applied to functional foods, nutritional supplements and pharmaceutical preparations, and is used for preventing or assisting in improving abnormal glucose and lipid metabolism.

Description

Technical Field

[0001] This invention relates to biomedical technology, specifically to a medium- and long-chain fatty acid oil-probiotic composition and its application in regulating blood sugar and blood lipids. Background Technology

[0002] With socioeconomic development and changes in lifestyle, the incidence of glucose and lipid metabolism-related diseases, such as diabetes, obesity, and metabolic syndrome, has been rising continuously. Multiple studies have shown that in recent years, the prevalence of glucose metabolism abnormalities such as impaired fasting glucose and impaired glucose tolerance, as well as lipid abnormalities such as hypercholesterolemia and hypertriglyceridemia, has been steadily increasing in the Chinese population, with a significantly increased burden on children, adolescents, and young adults, indicating a clear trend of glucose and lipid metabolism abnormalities affecting younger people. If glucose and lipid metabolism abnormalities are not addressed in a timely manner, they often progress to major chronic diseases such as diabetes and atherosclerotic cardiovascular disease, imposing a heavy burden on public health and the socioeconomic system.

[0003] Currently, the main medications used clinically to manage abnormal glucose and lipid metabolism include hypoglycemic agents (such as biguanides and sulfonylureas), insulin and its analogues, and lipid-lowering therapies represented by statins and fibrates. These medications are effective in improving metabolic indicators, but long-term use may increase the risk of hypoglycemia, liver and kidney damage, and muscle-related adverse reactions. For individuals in the early stages of glucose and lipid metabolism disorders or in a sub-healthy state, due to low adherence to medication interventions, intervention through lifestyle modifications remains the preferred strategy. Therefore, improving glucose and lipid metabolism through daily diet is of significant practical importance for sub-healthy individuals.

[0004] Myristic acid is a long-chain saturated fatty acid containing 14 carbon atoms, widely found in coconut oil, palm kernel oil, and dairy products. Studies have shown that myristic acid has potential functions such as immunomodulation and improving insulin resistance. However, currently available products rarely use myristic acid as the main fatty acid component and give it a clear functional positioning in the formulation design. Even more lacking is the systematic application of myristic acid in regulating blood sugar and blood lipids by combining it with functional oils such as medium-chain triglycerides and high-oleic vegetable oils, characterized by a high proportion of myristic acid in the total fatty acid content, and blending it with other functional oils such as medium-chain triglycerides and high-oleic vegetable oils.

[0005] Gut microbiota is closely related to metabolic diseases. Bifidobacteria, as an important group of probiotics, has potential roles in regulating gut microecological balance and metabolic health. Currently available technologies lack the ability to synthesize specific fatty acid / oil systems with Bifidobacterium pseudosporidis (Bifidobacterium pseudosporidis). Bifidobacterium pseudocatenulatum A combined systemic approach for regulating blood sugar and blood lipids. Summary of the Invention

[0006] Objective of the invention: To address the aforementioned problems, this invention constructs an oil-probiotic composition containing myristic acid and clarifies its effects in lowering blood sugar and blood lipids. This composition, by constructing an oil component with myristic acid as the main fatty acid and using it in combination with Bifidobacterium pseudosporidis, has shown good blood sugar and blood lipid-lowering effects in animal experiments, and can be used for nutritional intervention in populations with abnormal glucose and lipid metabolism.

[0007] Technical solution: The myristic acid-containing oil composition of the present invention includes myristic acid, medium-chain triglycerides and high-oleic sunflower seed oil, and the myristic acid content is 50-70 wt%, the medium-chain triglyceride content is 20-40 wt%, and the high-oleic sunflower seed oil content is 10-30 wt% based on the total mass of the oil composition.

[0008] The oil composition wherein the medium-chain triglyceride is a triglyceride with a fatty acid carbon chain length of C6 to C12.

[0009] A myristic acid-containing oil-probiotic composition, comprising the oil composition and a probiotic component, wherein the probiotic component is *Bifidobacterium pseudobulbarum* (…). Bifidobacterium pseudocatenulatum) .

[0010] The oil-probiotic composition wherein the Bifidobacterium pseudosporidis is strain BNCC134343.

[0011] The oil-probiotic composition, wherein the viable count of *Bifidobacterium pseudobulb* in the probiotic component is 1 × 10⁻⁶. 8 ~1×10 11 CFU / g.

[0012] The oil-probiotic composition is wherein the mass ratio of the oil composition to the probiotic component is 10:1 to 20:1.

[0013] The oil-probiotic composition is an oral formulation and further includes a pharmaceutically or food-acceptable carrier and / or excipients.

[0014] The method for preparing the oil and fat composition includes the following steps: S1. Weigh out myristic acid, medium-chain triglycerides and high-oleic sunflower seed oil; S2. The medium-chain triglycerides and high-oleic sunflower seed oil are heated and stirred at 50-70°C. S3. Add myristic acid to the mixture obtained in step S2, and continue stirring at 50-70°C until the mixture is homogeneous to obtain the oil composition.

[0015] The preparation method of the oil-probiotic composition includes the following steps: S1. The strain of Bifidobacterium pseudobulbarbital was activated using a bacterial solid culture medium and cultured anaerobicly at 33-40℃ for 24-72 hours to obtain the activated strain. S2. The activated strain is inoculated into a bacterial liquid culture medium and cultured anaerobically at 33-40℃ for 24-72 hours to obtain Bifidobacterium pseudobulb seed liquid. S3. Inoculate the seed culture into the bacterial liquid culture medium at an inoculation rate of 1-4%, and culture anaerobically at 33-40℃ for 24-72 h to obtain the fermentation broth; S4. Centrifuge the fermentation broth at 10000-12000 g for 10-15 min, collect the bacterial precipitate, and adjust the viable cell count to obtain the probiotic components; S5. The prepared oil composition is mixed with the probiotic component obtained in step S4 and the preselected carrier and / or excipients in proportion, and optionally homogenized, dried or filled to obtain the oil-probiotic composition.

[0016] The preparation method described herein includes a bacterial solid culture medium prepared from BBL medium and agar powder, and a bacterial liquid culture medium prepared from an aqueous solution of BBL medium. The BBL medium contains peptone, glucose, yeast extract, soluble starch, sodium chloride, L-cysteine, tomato extract, liver extract, and Tween.

[0017] The use of the myristic acid-containing oil composition or the myristic acid-containing oil-probiotic composition in the preparation of pharmaceuticals or health products for the prevention and / or treatment of disorders of blood sugar and / or blood lipid metabolism.

[0018] Preferably, the disorders of blood glucose and / or lipid metabolism include diabetes mellitus. More preferably, the disorders of blood glucose and / or lipid metabolism include type 2 diabetes mellitus.

[0019] The use of the myristic acid-containing oil composition or the myristic acid-containing oil-probiotic composition in the preparation of drugs or health products for lowering blood sugar and / or lowering blood lipids.

[0020] A myristic acid-containing oil-probiotic composition, the composition comprising an oil component and a probiotic component; wherein the oil component has myristic acid as the main fatty acid; the oil component further comprises medium-chain triglycerides and a functional oil, the functional oil being high-oleic sunflower seed oil; the probiotic component is *Bifidobacterium pseudosporidis* (…). Bifidobacterium pseudocatenulatum ).

[0021] Furthermore, the medium-chain triglyceride is a triglyceride with a fatty acid carbon chain length of C6 to C12.

[0022] Furthermore, in the oil components, by mass percentage, myristic acid is 50-70 wt%, medium-chain triglycerides are 20-40 wt%, and high-oleic sunflower seed oil is 10-30 wt%.

[0023] Furthermore, the viable count of *Bifidobacterium pseudobulb* in the probiotic component is 1 × 10⁻⁶. 8 ~1×10 11 CFU / g, preferably 1×10 9 ~1×10 11 CFU / g.

[0024] Furthermore, the specific preparation method of the probiotic components is as follows: S1. Bifidobacterium pseudobulb was revived and purified to prepare Bifidobacterium pseudobulb seed solution; S2. The seed culture of Bifidobacterium pseudosporidis obtained in step S1 is inoculated into a bacterial liquid culture medium for anaerobic culture, and then the precipitate is collected after centrifugation.

[0025] Furthermore, the method for preparing the Bifidobacterium pseudobulb seed culture in step S1 is as follows: The *Bifidobacterium pseudobulbarbiturum* strain was activated using a bacterial solid culture medium and anaerobically cultured at 37°C for 24–48 h. The activated strain was then inoculated into a bacterial liquid culture medium and anaerobically cultured at 37°C for 24–48 h to obtain *Bifidobacterium pseudobulbarbiturum* seed culture.

[0026] Furthermore, the preparation method of the bacterial solid culture medium is as follows: weigh 51g of BBL culture medium and 15g of agar powder, add 1L of distilled water, stir evenly, autoclave at 121℃ for 15min, invert the plate and let it solidify for later use.

[0027] Furthermore, the preparation methods for the seed liquid and the bacterial liquid culture medium in step S2 are as follows: weigh 51g of BBL culture medium, add 1L of distilled water, stir evenly, and autoclave at 121℃ for 15min.

[0028] Furthermore, the BBL medium is formulated as follows: peptone 15 g / L, glucose 20 g / L, yeast extract 2 g / L, soluble starch 0.5 g / L, sodium chloride 5 g / L, L-cysteine ​​0.5 g / L, tomato extract 5 g / L, liver extract 2 g / L, and Tween 80 1 g / L.

[0029] Furthermore, in step S1, the inoculation amount of Bifidobacterium pseudobulb seed liquid is 1-4% of the mass of the bacterial liquid culture medium.

[0030] Furthermore, in step S2, the anaerobic culture temperature is 37°C, and the culture time is 24~72h.

[0031] Furthermore, the method for extracting the bacterial precipitate is as follows: the fermentation broth in step S2 is separated by centrifugation.

[0032] Furthermore, the centrifugation speed is 10000~12000g, and the centrifugation time is 10~15min.

[0033] In addition, the present invention also provides a method for preparing the above-mentioned oil-probiotic composition containing myristic acid, the preparation method comprising: S1. Weigh myristic acid, medium-chain triglycerides and high-oleic sunflower seed oil according to a predetermined ratio, heat and stir them at 50-70℃ to obtain an oil component with a fatty acid composition that meets the set range. S2. Provides Bifidobacterium pseudosporidis bacterial precipitate and adjusts the viable count to the set range; S3. The oil component is mixed with Bifidobacterium pseudosporidis and preselected carriers and / or excipients in a certain proportion, and optionally homogenized, dried or filled to obtain the oil-probiotic composition containing myristic acid.

[0034] Furthermore, the composition is an oral formulation comprising an effective amount of the above-prepared myristic acid oil-probiotic mixture and pharmaceutically or food-acceptable excipients.

[0035] This invention uses myristic acid as the main fatty acid, constructing an oil component with specific fatty acid composition characteristics by combining it with medium-chain triglycerides and high-oleic vegetable oils, and then combining it with Bifidobacterium pseudomicrobium to form an oil-probiotic composition. On the one hand, the myristic acid content range in the oil component is clearly defined, which is beneficial for product formulation standardization and quality control; on the other hand, by combining this oil component with specific probiotic strains, lipid nutrition regulation and intestinal microecological regulation can be achieved in the same composition. Animal experimental results show that, compared with the model control group, the myristic acid-containing oil-probiotic composition provided by this invention can significantly reduce fasting blood glucose levels in high-fat diet-induced type 2 diabetes model animals, and significantly reduce serum total cholesterol (TCHO) and triglycerides (TG), demonstrating a good ameliorative effect on abnormal glucose and lipid metabolism.

[0036] Beneficial effects: Compared with the prior art, the present invention has the following advantages: (1) It provides a functional oil composition with a clear fatty acid composition and myristic acid as the main fatty acid, and defines the mass percentage range of myristic acid and the ratio between it and medium-chain triglycerides and high-oleic sunflower seed oil. The formula structure is clear and easy to industrialize and control quality; (2) It creatively combines the above-mentioned oil components with Bifidobacterium pseudomicrobium to form an oil-probiotic composition, which simultaneously achieves lipid nutrition intervention and intestinal microecological intervention in a single product; (3) Animal experiments have verified that the composition of the present invention can significantly reduce fasting blood glucose and blood lipid levels in model animals and has a good effect on improving abnormal glucose and lipid metabolism. At the same time, the oil raw materials selected in the present invention are all lipid components that can be safely used in the food field, and have good intake safety and tolerability. The Bifidobacterium pseudomicrobium selected in the probiotic part is a symbiotic strain from the intestine, which has a clear potential for metabolic improvement in related studies and can be used for the development of nutritional intervention compositions, with good application prospects. Attached Figure Description

[0037] Figure 1 The effects of myristic acid, Bifidobacterium pseudoshort chain, a mixture of medium-chain triglycerides and high-oleic sunflower seed oil, and compositions A to C on fasting blood glucose in mice;

[0038] Figure 2 The effects of myristic acid, Bifidobacterium pseudoshort chain, a mixture of medium-chain triglycerides and high-oleic sunflower seed oil, and compositions A to C on glucose tolerance in mice;

[0039] Figure 3 The effects of myristic acid, Bifidobacterium pseudoshort chain, medium-chain triglycerides-high oleic sunflower oil mixture, and the composition on serum total triglycerides and total cholesterol in mice A-C. Detailed Implementation

[0040] The present invention will be further described below with reference to specific embodiments, but the present invention is not limited to the following embodiments. Without departing from the spirit and essence of the present invention, those skilled in the art can make various equivalent substitutions or modifications, all of which fall within the protection scope of the present invention.

[0041] Unless otherwise specified, reagents used in the following examples and comparative examples are conventional reagents and can be purchased from conventional reagent manufacturers and distributors. Unless otherwise specified, the methods used are existing technologies. Medium-chain triglycerides were purchased from Shanghai Yuanye (product number: S25953). High-oleic sunflower oil was purchased from Wuhan Beileye (product number: BLY3876).

[0042] Example 1 The preparation of oil mixture A containing myristic acid includes the following steps: Weigh out 5.5g of myristic acid, 2.5g of medium-chain triglycerides, and 2.0g of high-oleic sunflower seed oil. Based on this ratio, myristic acid accounts for 55wt%, medium-chain triglycerides account for 25wt%, and high-oleic sunflower seed oil accounts for 20wt% of the total oil components.

[0043] (1) Under stirring conditions, add pre-measured medium-chain triglycerides and high-oleic sunflower oil.

[0044] (2) Add myristic acid, heat at 60°C, and continue stirring for 10 minutes to make the mixture uniform to obtain composition A.

[0045] Example 2 The preparation of composition B containing myristic acid-Bifidobacterium pseudomicrobium includes the following steps: (1) Preparation of Bifidobacterium pseudosporidis Bifidobacterium pseudobulb (strain number: BNCC134343) purchased from Beina Biotechnology was inoculated onto BBL solid medium and cultured anaerobically at 37°C for 48 h to activate the strain. Two loops of the activated strain were then inoculated into 8 mL of BBL liquid medium and cultured for another 48 h in an anaerobic incubator at 37°C to obtain a seed culture of Bifidobacterium pseudobulb. A 2% inoculum was then added to 50 mL of BBL liquid medium and cultured under the same conditions for 48 h. After the culture was completed, the OD600 of the bacterial culture was adjusted to achieve a viable count of approximately 1 × 10⁻⁶. 9 CFU / g. Finally, the precipitate was collected by centrifugation at 12000g for 15 min to obtain the bacterial sludge.

[0046] (2) Preparation of composition B Weigh 5.5g of myristic acid into 10mL of 10% fatty acid-free bovine serum albumin (BSA) solution and stir to obtain a myristic acid mixture. Weigh each component according to the mass ratio of myristic acid to Bifidobacterium pseudosporphyria sludge = 10:1, mix well, and obtain the oil-bacterial powder composition B containing myristic acid.

[0047] Example 3 The preparation of composition C containing myristic acid-medium-chain triglycerides-high oleic sunflower seed oil-Bifidobacterium pseudomicrobium includes the following steps: (1) Preparation of oil components Oil mixture A was prepared according to the method of Example 1, such that myristic acid accounted for 55 wt% of the total fatty acids.

[0048] (2) Preparation of freeze-dried Bifidobacterium pseudobulb powder Bifidobacterium pseudosporidis was prepared according to the method described in Example 2 (1), with a viable count of approximately 1 × 10⁻⁶. 9 CFU / g.

[0049] (3) Preparation of composition C Weigh each component according to the mass ratio of oil mixture A: Bifidobacterium pseudosporidis = 10:1, stir thoroughly to make it uniform, and obtain composition C.

[0050] Example 4 The application of composition C in a type 2 diabetes animal model includes the following steps: (1) Animal grouping and administration Forty male C57BL / 6J mice aged 6–8 weeks (20-23g, purchased from Jiangsu Jicui Pharmaceutical Co., Ltd.) were selected and randomly divided into 8 groups (n=5 per group) after acclimatization to a standard diet for 5 days: healthy control group (NC), model control group (T2DM), myristic acid treatment group (MA), oil treatment group (Oil), Bifidobacterium pseudosporidis treatment group (Bp), combination A treatment group (A), combination B treatment group (B), and combination C treatment group (C). Except for the healthy control group, which was continuously fed a standard diet, all other groups were fed a high-fat diet (HFD, 60% fat energy). After 4 weeks of continuous HFD feeding, the model control group and all treatment groups were intraperitoneally injected with streptozotocin (STZ, 50 mg / kg) for 5 consecutive days to induce a type 2 diabetes model. Fasting blood glucose levels were measured two weeks later; a fasting blood glucose level >16.6 mmol / L was considered a successful model establishment. After successful model establishment, drug intervention was initiated, with administration every 2 days for a total of 4 weeks. The dosage settings for each treatment group were as follows: the MA group received 300 mg / kg MA; the Oil group received a mixture of 300 mg / kg medium-chain triglycerides and high-oleic sunflower oil (where the ratio of medium-chain triglycerides to high-oleic sunflower oil was 5:4); and the Bp group received 1 × 10⁻⁶ mg / kg MA. 8 CFU / mouse; Groups A, B, and C were administered the corresponding composition at 300 mg / kg. Control and model mice were administered an equal volume of PBS as a control.

[0051] (2) Fasting blood glucose measurement and glucose tolerance test (GTT) In the last week of drug administration, fasting blood glucose levels were measured in mice. After fasting for 8 hours (with free access to water during this period), blood was collected from the tail tip, and fasting blood glucose levels were measured using a handheld glucometer.

[0052] The glucose tolerance test (GTT) was then performed. Mice were fasted for 8 hours and then injected intraperitoneally with a 2 g / kg glucose solution. Blood glucose levels were measured by collecting blood samples from the tail tip at 0, 30, 60, 90, and 120 minutes. The resulting glucose-time curves were used to calculate the area under the glucose tolerance curve (AUC) to assess the body's ability to clear glucose load.

[0053] (3) Blood lipid index measurement At the end of the experiment, mice were fasted for 12 hours, then anesthetized, and euthanized after blood was collected from their eyeballs. The blood was centrifuged at 3000 rpm for 10 minutes to separate serum. Serum TCHO and TG levels were measured using commercial kits (Solarbio) according to the manufacturer's instructions.

[0054] (4) Experimental results like Figure 1 As shown, compared with the T2DM model group, compositions A to C all significantly reduced fasting blood glucose levels in diabetic mice. p <0.05), with composition C showing the largest reduction, reaching 33.27%. To assess whether the combined drug effect exceeded the simple additive effect of each component alone, the sum of the improvement magnitudes of the three components individually was used as the additive expected value for comparison. The results showed that the improvement magnitudes of each drug component in the MA, BP, and Oil groups when used alone were 16.45%, 5.67%, and 1.58%, respectively, with an additive expected value of 23.70%; while the actual improvement magnitude of composition C was 33.27%, which was 9.57 percentage points higher than the expected value, suggesting that the combination of the three components has a synergistic effect.

[0055] Figure 2 The glucose tolerance test (GTT) results shown further support the above conclusions. Compared with the T2DM group, compositions A through C significantly reduced the area under the glucose tolerance test curve (AUC). p <0.05), with composition C showing the largest reduction (21.36%). The individual interventions of MA, BP, and Oil improved GTT-AUC by 5.97%, 2.56%, and 1.84%, respectively, with an additive expected value of 10.37%. Composition C, however, showed an actual improvement of 21.36%, exceeding the expected value by 10.99 percentage points, indicating a synergistic effect in improving glucose tolerance disorders.

[0056] like Figure 3 As shown, composition C also exhibited significant additive and improving effects on blood lipid indicators. Regarding TG, the individual improvements of each drug component in the MA, BP, and Oil groups were 14.60%, 5.59%, and 5.18%, respectively, with an additive expected value of 25.37%; while the actual improvement of composition C was 36.02%, exceeding the expected value by 10.65 percentage points. Regarding T-CHO, the individual improvements of each component were 7.99%, 7.77%, and 8.07%, respectively, with an additive expected value of 23.83%; the actual improvement of composition C was 37.56%, exceeding the expected value by 13.73 percentage points. Figure 3 ).

[0057] In summary, myristic acid has a synergistic effect when used in combination with specific oils or probiotics, and the complex formed by the three (composition C) showed the best effect in improving fasting blood glucose, glucose tolerance and lipid metabolism in type 2 diabetic mice, suggesting its potential application value in metabolic regulation.

Claims

1. A myristoleic acid-containing oil and fat composition, characterized by, The oil composition comprises myristic acid, medium-chain triglyceride and high-oleic sunflower oil, and the mass percentage of myristic acid is 50-70 wt%, the mass percentage of medium-chain triglyceride is 20-40 wt%, and the mass percentage of high-oleic sunflower oil is 10-30 wt% based on the total mass of the oil composition.

2. The oil composition according to claim 1, characterized by, The medium-chain triglyceride is a triglyceride with a fatty acid carbon chain length of C6-C12.

3. A myristoleic acid containing oil-probiotic composition, characterized in that, The oil and fat composition according to any one of claims 1 or 2, further comprising a probiotic component, wherein the probiotic component is Bifidobacterium pseudocatenulatum (ATCC 2799) Bifidobacterium pseudocatenulatum .

4. The fat-probiotic composition according to claim 3, characterized in that, The Bifidobacterium pseudocatenulatum is a strain with the strain number BNCC134343.

5. The fat-probiotic composition according to claim 3 or 4, characterized in that, The viable cell count of B. pseudocatenulatum in the probiotic component is 1 x 10 8 ~ 1 x 10 11 CFU / g.

6. The fat-probiotic composition according to any one of claims 3 to 5, characterized in that, The mass ratio of the oil composition to the probiotic component is 10:1-20:

1.

7. The fat-probiotic composition according to any one of claims 3 to 6, characterized in that, The composition is an oral preparation, further comprising a pharmaceutically or food acceptable carrier and / or excipient.

8. A method for producing the oil-and-fat composition according to claim 1 or 2, characterized by, The method comprises the following steps: S1, weighing myristic acid, medium-chain triglyceride and high-oleic sunflower oil; S2, heating and stirring the medium-chain triglyceride and high-oleic sunflower oil under the condition of 50-70℃; S3, adding myristic acid to the mixture obtained in step S2, and continuing to stir under the condition of 50-70℃ until the mixture is uniformly mixed, to obtain the oil composition.

9. A method for preparing the fat-probiotic composition according to any one of claims 3 to 7, characterized in that, The method comprises the following steps: S1, activating the Bifidobacterium pseudocatenulatum strain using a bacterial solid culture medium, and anaerobically culturing at 33-40℃ for 24-72 h to obtain an activated strain; S2, inoculating the activated strain into a bacterial liquid culture medium, and anaerobically culturing at 33-40℃ for 24-72 h to obtain a Bifidobacterium pseudocatenulatum seed liquid; S3, inoculating the seed liquid into a bacterial liquid culture medium at an inoculation amount of 1-4%, and anaerobically culturing at 33-40℃ for 24-72 h to obtain a fermentation liquid; S4, centrifuging the fermentation liquid at 10000-12000 g for 10-15 min, collecting the bacterial precipitate, and adjusting the viable bacterial count to obtain a probiotic component; S5, mixing the oil composition prepared by the preparation method of claim 8 with the probiotic component obtained in step S4 and a preselected carrier and / or excipient in a proportion, and optionally performing homogenization, drying or filling treatment to obtain the oil-probiotic composition.

10. Use of the myristic acid-containing oil composition of claim 1 or the myristic acid-containing oil-probiotic composition of claim 3 in the preparation of a medicine or health product for preventing and / or treating abnormal glucose and / or lipid metabolism diseases.

Images